2022 World Conference on Lung Cancer (ePosters)-EP08.02-030. Tusamitamab Ravtansine in Patients with NSQ NSCLC and Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

EP08.02-030. Tusamitamab Ravtansine in Patients with NSQ NSCLC and Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

Pdf Summary

Summary Not Available

Asset Subtitle

Christine Soufflet

Meta Tag

Speaker Christine Soufflet

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments